熱門資訊> 正文
Sangamo Therapeutics申请第11章破产
2026-06-23 18:06
- Biotech firm Sangamo Therapeutics (SGMO) is said to have filed for Chapter 11 bankruptcy protection in Delaware on Tuesday, reporting both assets and liabilities estimated between $100M and $500M as it seeks to navigate its worsening financial constraints.
- The company had recently retained Raymond James as its financial advisor to assist in evaluating a full range of strategic alternatives to advance its promising pipeline and to maximize value for all stakeholders.
More on Sangamo Therapeutics
- Sangamo Therapeutics, Inc. (SGMO) Presents at 29th ASGCT Annual Meeting 2026 - Slideshow
- Sangamo Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation
- Sangamo Therapeutics, Inc. (SGMO) Q1 2026 Earnings Call Transcript
- Sangamo anticipates completing ST-920 BLA submission as early as this summer while appealing NASDAQ delisting in June
- Sangamo Therapeutics Q1 2026 Earnings Preview
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
